290 related articles for article (PubMed ID: 33299117)
1. Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma.
Tada H; Takahashi H; Kawabata-Iwakawa R; Nagata Y; Uchida M; Shino M; Ida S; Mito I; Matsuyama T; Chikamatsu K
Sci Rep; 2020 Dec; 10(1):21573. PubMed ID: 33299117
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of circulating tumor cells predicts clinical outcome in head and neck squamous cell carcinoma.
Tada H; Takahashi H; Kuwabara-Yokobori Y; Shino M; Chikamatsu K
Oral Oncol; 2020 Mar; 102():104558. PubMed ID: 32044652
[TBL] [Abstract][Full Text] [Related]
3. Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
Ida S; Takahashi H; Tada H; Mito I; Matsuyama T; Chikamatsu K
Oral Oncol; 2023 Feb; 137():106296. PubMed ID: 36571985
[TBL] [Abstract][Full Text] [Related]
4. The Blood Microenvironment Influences the Molecular Phenotypes of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma.
Tada H; Takahashi H; Ida S; Mito I; Matsuyama T; Chikamatsu K
Anticancer Res; 2021 Feb; 41(2):885-893. PubMed ID: 33517294
[TBL] [Abstract][Full Text] [Related]
5. Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma.
Chikamatsu K; Tada H; Takahashi H; Kuwabara-Yokobori Y; Ishii H; Ida S; Shino M
Oral Oncol; 2019 Feb; 89():34-39. PubMed ID: 30732956
[TBL] [Abstract][Full Text] [Related]
6. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Payne K; Pugh M; Brooks J; Batis N; Taylor G; Nankivell P; Mehanna H
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153130
[TBL] [Abstract][Full Text] [Related]
8. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
Tinhofer I; Hristozova T; Stromberger C; Keilhoiz U; Budach V
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e685-90. PubMed ID: 22583603
[TBL] [Abstract][Full Text] [Related]
11. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Taura M; Uchi R; Nakagawa T
Oral Oncol; 2020 Feb; 101():104525. PubMed ID: 31863963
[TBL] [Abstract][Full Text] [Related]
12. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
[TBL] [Abstract][Full Text] [Related]
14. Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab.
Nishikawa D; Suzuki H; Beppu S; Terada H; Sawabe M; Kadowaki S; Sone M; Hanai N
Cancer Sci; 2021 Jan; 112(1):339-346. PubMed ID: 33078505
[TBL] [Abstract][Full Text] [Related]
15. Characterization of different CTC subpopulations in non-small cell lung cancer.
Hanssen A; Wagner J; Gorges TM; Taenzer A; Uzunoglu FG; Driemel C; Stoecklein NH; Knoefel WT; Angenendt S; Hauch S; Atanackovic D; Loges S; Riethdorf S; Pantel K; Wikman H
Sci Rep; 2016 Jun; 6():28010. PubMed ID: 27302574
[TBL] [Abstract][Full Text] [Related]
16. Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma.
Zavridou M; Mastoraki S; Strati A; Koutsodontis G; Klinakis A; Psyrri A; Lianidou E
Sci Rep; 2020 Apr; 10(1):6551. PubMed ID: 32300118
[TBL] [Abstract][Full Text] [Related]
17. Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma.
Inoue H; Yokota T; Hamauchi S; Onozawa Y; Kawakami T; Shirasu H; Notsu A; Yasui H; Onitsuka T
Auris Nasus Larynx; 2020 Aug; 47(4):650-657. PubMed ID: 32035695
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma.
Hsieh JC; Lin HC; Huang CY; Hsu HL; Wu TM; Lee CL; Chen MC; Wang HM; Tseng CP
Head Neck; 2015 Oct; 37(10):1448-55. PubMed ID: 24844673
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
20. A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers.
Hristozova T; Konschak R; Budach V; Tinhofer I
Cytometry A; 2012 Jun; 81(6):489-95. PubMed ID: 22438318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
